|22nd December 2020||Jay Venkatesan||181,024||Other acquisition or disposition||$0.00|
|22nd December 2020||Jay Venkatesan||993,801||Other acquisition or disposition||$0.00|
|14th October 2020||Bali Muralidhar||200,000||Open or private purchase||$15.00||$3,000,000.00|
|14th October 2020||Bali Muralidhar||1,592,518||Conversion of derivative||$0.00|
|6th July 2020||Jay Venkatesan||9,310||Exercise of derivative||$0.65||$6,051.50|
|6th July 2020||Jay Venkatesan||12,930||Exercise of derivative||$1.03||$13,317.90|
|12th June 2020||Llc Aurasense||10,195||Open or private sale||$2.83||$28,851.85|
|12th June 2020||Chad A. Mirkin||10,195||Open or private sale||$2.83||$28,851.85|
|20th May 2020||Chad A. Mirkin||49,649||Exercise of derivative||$0.65||$32,271.85|
|13th March 2020||David R Walt||291,066||Open or private purchase||$1.21||$352,859.31|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Exicure, Inc. engages in the provision of clinical stage biotechnology company. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.